Pancreatic ductal adenocarcinoma (PDAC) remains resistant to chemotherapy and immunotherapy individually because of its desmoplastic stroma and immunosuppressive tumor microenvironment. Synergizing cytotoxic T‐lymphocyte–associated antigen 4 (CTLA‐4) immune checkpoint blockade with chemotherapy could overcome these barriers.
Here we present results of a phase Ib trial combining ipilimumab and gemcitabine in advanced PDAC. Read more . . .
Let’s Win! Pancreatic Cancer is an online community for sharing information about innovative, science-based treatments for pancreatic cancer. Please note that this information is not intended to be a substitute for professional medical opinion, advice, or diagnosis. We encourage you to use this information to begin a dialogue with your physician about the treatment plan that is right for you.